Search

Displaying results 2551 - 2560 of 10000 in total
  1. Drug

    Dinalbuphine sebacate

    go.drugbank.com/drugs/DB15341
    Investigational

    Dinalbuphine sebacate is under investigation in clinical trial NCT02468128 (A Study of Intramuscular Sebacoyl Dinalbuphine Ester for Post-Hemorrhoidectomy Pain Management).

    Products: NALDEBAIN® EXTENDED RELEASE INJECTION 75MG/ML
  2. Drug

    Ethinamate

    go.drugbank.com/drugs/DB01031
    ApprovedIllicitWithdrawn

    Structurally, it does not resemble the barbituates, but it shares many effects with this class of drugs; the depressant effects of ethinamate are, however, generally milder than those of most barbiturates … Nevertheless, the medication itself is generally no longer effective after using it for greater than 7 days.

  3. Drug

    Florfenicol

    go.drugbank.com/drugs/DB11413
    ExperimentalVet approved

    Florfenicol is a fluorinated synthetic analog of thiamphenicol.

    Products: Florcol Oral Solution 250mg/ml
  4. Drug

    Acetrizoic acid

    go.drugbank.com/drugs/DB09347
    ApprovedWithdrawn

    [A32135] It was first synthesized by Wallingford in 1953[A32136] and it was filled in the FDA by the Johnson & Johnson subsidiary, Cilag Chemie AG, on February 8th, 1978. … Acetrizoic acid presents the molecular formula of 3-acetamidol-2,4,6-triiodobenzoic acid[L1702] and it is the first monomeric ionic compound used as an X-ray contrast agent.

  5. Drug

    LI-301

    go.drugbank.com/drugs/DB05509
    Experimental

    It has a novel mode of action combining both the light effect of a Selective Serotonin Reuptake Inhibitor ("SSRI")(most likely antagonistic at 5HT1a receptors) and antagonism at mu-opioid receptors. … LI 301 is an orally bio-available compound delivered in a fast melt mechanism with taste masking enabling it to be taken anytime without water.

  6. Drug

    Pancrelipase lipase

    go.drugbank.com/drugs/DB13147
    ApprovedInvestigational

    [A32748] The pancrelipase mixture, including pancrelipase lipase, was developed by Ortho-McNeil-Janssen Pharmaceuticals, Inc and FDA approved on April 12, 2010.[L2510]

    Mixtures: Pancrease Mt 10, Pancrease Mt 20Products: Formula C & E
  7. Drug

    Ledipasvir

    go.drugbank.com/drugs/DB09027
    Approved

    It is effective against genotypes 1a, 1b, 4a, and 5a and with a lesser activity against genotypes 2a and 3a of HCV. … Although its exact mechanism of action is unknown, it is postulated to prevent hyperphosphorylation of NS5A which is required for viral protein production.

    Mixtures: HARVONI 90 MG/400 MG FILM KAPLI TABLET, 84 ADET, HARVONI 90 MG/400 MG FILM KAPLI TABLET, 28 ADET
  8. Drug

    Inebilizumab

    go.drugbank.com/drugs/DB12530
    ApprovedInvestigational

    [A214280, A214289, A214292, A214295, A214298, A214301] Inebilizumab was granted initially FDA approval on June 11, 2020, for the treatment of anti-aquaporin 4 positive NMOSD patients. … [L14315] Given its mechanism of action and good safety profile, it may prove useful in the treatment of other conditions linked to autoimmune antibody production or B-cell malignancies.

  9. Drug

    CIGB 300

    go.drugbank.com/drugs/DB16464
    Investigational

    CIGB-300, is under investigation in clinical trials for its potential to treat various conditions, including NCT01639638 (recurrent and nonrecurrent condyloma) and NCT01639625 (squamous cell carcinoma

  10. Drug

    Abaloparatide

    go.drugbank.com/drugs/DB05084
    ApprovedInvestigational

    [L740] In October 2022, the EMA's Committee for Medicinal Products for Human Use (CHMP) recommended abaloparatide be granted marketing authorization in Europe [L43552] and the drug was fully authorized … [L740] It is a synthetic 34 amino acid peptide with 41% homology to human parathyroid hormone 1-34 and human PTHrP 1-34.